Valuation: Quest PharmaTech Inc.

Market Cap 42.28L 29.77L 26.02L 23.92L 22.29L 28Cr 42.92L 2.87Cr 1.12Cr 14Cr 1.12Cr 1.09Cr 48Cr P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 52.14L 36.71L 32.09L 29.49L 27.49L 35Cr 52.93L 3.54Cr 1.38Cr 17Cr 1.38Cr 1.35Cr 59Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 week+25.00%
1 month-16.67%
3 months-16.67%
6 months-37.50%
Current year-28.57%
1 week 0.02
Extreme 0.025
0.02
1 month 0.02
Extreme 0.02
0.04
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.1
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap.
12/12OtherCompany 0 0%
21/25/21Other

Chief Executive Officer

10,00,000 0.5913%
21/25/21Other

Chief Executive Officer

7,00,000 0.4139%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+25.00%-28.57%-66.67% 29.77L
+1.70%+7.41%+2.50%+8.18% 4.99TCr
+0.92%+3.93%+399.71%+604.02% 4.02TCr
+1.89%+8.32%+26.06%-6.27% 3.46TCr
+2.38%+6.35%+21.25%+55.45% 3.31TCr
+3.96%+10.67%+8.30%+37.95% 2.75TCr
+2.51%+5.27% - - 1.7TCr
+2.58%+5.79%+73.44%+135.37% 1.59TCr
+0.32%+0.58%+14.00%+19.09% 1.39TCr
+3.30%+0.76%+90.23%+93.88% 1.35TCr
Average +1.96%+7.74%+67.44%+97.89% 2.46TCr
Weighted average by Cap. +2.07%+6.53%+90.20%+135.86%

Financials

2025 2026
Net sales - -
Net income -18.01L -12.68L -11.09L -10.19L -9L -12Cr -18.28L -1.22Cr -47.54L -5.93Cr -47.6L -46.57L -20Cr 49.98L 35.19L 30.76L 28.27L 26.35L 34Cr 50.74L 3.39Cr 1.32Cr 16Cr 1.32Cr 1.29Cr 57Cr
Net Debt 8L 6L 5L 4L 4L 5.33Cr 8L 53.98L 20.98L 2.62Cr 21.01L 20.56L 9.03Cr 10L 7L 6L 6L 5L 6.61Cr 10.01L 66.93L 26.02L 3.25Cr 26.05L 25.49L 11Cr
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
03/26/03 CA$0.0250 0.00% 15,000
02/26/02 CA$0.0250 0.00% 5,000
30/26/30 CA$0.0250 0.00% 42,901
29/26/29 CA$0.0250 +25.00% 99,075